third-quart new ceo year-end heavi data earli
thursday octob market close gilead report third quarter
manag increas total revenu guidanc slightli
billion billion maintain guidanc gross margin
expens sg expens effect tax rate expect come
financi result exhibit revenu quarter billion estim
billion consensu billion hiv franchis revenu came billion
beat consensu estim billion repres growth second
quarter world-wide hcv revenu million line estim
million beat consensu million demonstr sequenti declin
second quarter yescarta sale million lower estim
million consensu estim million bottom line non-gaap ep
quarter beat estim consensu complet
varianc analysi expect consensu actual result quarter
summar exhibit
increas estim note third
quarter hiv beat driven favor payer mix strong uptak biktarvi
stabil inventori channel increas hiv product sale estim
slightli billion billion previous hcv franchis exhibit
sequenti drop second quarter manag expect slow steadi declin
move forward continu estim hcv product sale billion lastli
yescarta miss third quarter lower yescarta sale estim
million million previous base chang third-quart
beat increas full year product revenu estim billion
billion previous rais full-year non-gaap ep estim
return equiti ttm
gilead research-bas biotechnolog compani focus develop therapi treatment life-
threaten diseas gilead leader hiv/aid therapeut recent hcv also
larg product portfolio includ therapeut liver cardiovascular inflammatori respiratori diseas
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
gilead share pull back due varieti factor includ advers macroenviron uncertainti ceo
senior manag placement slower-than-expect yescarta roll-out fear hcv franchis
declin howev continu hold long-term posit view gilead share due strong hiv franchis
growth stabil hcv franchis dividend yield promis cell therapi field major upcom
phase data readout new ceo name year-end sum-of-the-part valuat
analysi continu show fair valu exhibit model continu recogn year
rel flat year return growth upcom pipelin catalyst includ
data earli would lead first nda file filgotinib rheumatoid arthriti ra
data first half selonsertib nash dcf analys hiv hcv franchis lead valuat
per share respect late stage asset expect read phase data valu filgotinib
per share probabl success rheumatoid arthriti probabl success ulcer
coliti crohn diseas valu selonsertib per share advanc nash probabl success
addit valu yescarta next gener product candid per share includ per share net cash
year-end deriv fair valu estim gilead share
biktarvi becam prescrib regimen treatment-nav patient third quarter overtak
genvoya top hiv agent ever launch support gilead continu hiv franchis domin exhibit
biktarvi b/f/taf approv februari mark compani eighth final combin
regimen develop hiv platform lifelong control hiv infect second full quarter market
biktarvi brought million volum come switch patient came
patient previous dolutegravir-contain regimen came genvoya patient rapid rate
adopt biktarvi exceed genvoya previous grab top spot launch uptak among
hcv regimen unlik genvoya requir pharmacokinet booster cobicistat biktarvi need
booster improv safeti profil posit biktarvi becom primari option treatment-nav
switch patient march biktarvi ad depart human servic
guidelin use anti-retrovir agent adult adolesc live hiv one recommend
initi regimen earlier week journal american medic associ publish updat treatment
guidelin aid societi biktarvi recommend addit total hiv script volum
increas year-over-year reflect gilead preemin field continu expect compani hiv
franchis continu hold absolut domin hiv market current market share
grow forecast sustain growth first next-gener taf-
hcv revenu continu slow steadi declin third quarter sequenti growth
manag continu expect hcv market fulli stabil year-end exhibit competit
outperform appear stabil market share reach equilibrium expect
slow steadi overal declin market contract continu ascrib matur market share
mavyret gilead franchis due mavyret simpl algorithm competit profil long term
current project sale hcv franchis gilead billion potenti
upsid gilead estim could come sale hcv franchis product china intern
yescarta third full quarter market miss expect million book competit
continu intensifi novarti nv gilead race launch respect lead car-t
kymriah yescarta across transplant center unit state third quarter novarti book
million sale kymriah two approv indic pediatr acut lymphoblast leukemia r/r
diffus larg b-cell lymphoma dlbcl gilead achiev author center end
third quarter estim roughli center need cover elig r/r dlbcl patient
unit state first-mov advantag set base compani site activ trajectori
geography-bas strategi roughli patient within reason distanc certifi transplant
center current europ follow approv yescarta compani plan complet author
center germani franc
look numer near-term catalyst drive growth beyond declin hcv franchis sale nash
expect phase ii data studi fxr agonist fourth quarter follow data two phase
studi inhibitor selonsertib first half phase studi
evalu selonsertib monotherapi nash patient bridg fibrosi cirrhosi respect
posit trial could lead regulatori file selonsertib end phase iib combin studi
selonsertib /- /- inhibitor advanc nash expect read interim data
fourth quarter data second third three phase studi filgotinib
rheumatoid arthriti anticip first quarter could lead first regulatori file
asset beyond candid gilead continu pursu develop broad pipelin span hiv hbv
liver diseas immunolog oncolog well label expans approv agent
strateg develop deploy capit remain key goal continu believ gilead provid
long-term opportun valu growth strong investor return includ good dividend yield
robust share buy-back program manag continu comment compani continu evalu strateg
deal priorit use capit invest long-term growth recent exemplifi recent
collabor deal sangamo verili gadeta view oncolog liver diseas
inflamm area high interest develop believ addit strateg acquisit could take
place near futur enhanc compani pipelin bolster growth
risk outperform thesi includ compani depend hiv franchis repres fundament
concentr risk investor magnitud speed declin hcv franchis launch yescarta could miss
expect safeti risk market could lead stock volatil continu pipelin expans cellular therapi
clinic risk filgotinib selonsertib phase studi pipelin asset
hcv product royalti contract total sg total oper interest expens incom expens pre-tax provis incom net net incom loss attribut non-controlling net incom attribut non- reconciliationcost good sold expens sg expens interest expens adjustments- total non- adjust incom tax effect tax reform total non- adjust non- net incom attribut non- dividend per common weight averag share outstand weight averag share outstand compani report william blair scienc inc incom statement william blair
actualwb estimatespreadvarianceq/q growthy/i growthcon hcv hiv product cost expensescost good gener net incom attribut ep compani report william blair estimatescurr scienc inc current quarter varianc analysi dollar million except ep william blair
drugpeak sale stage ofdevelopmentestimatedlaunch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuehiv phase phase year-end present valu addit loss fair includ cost directli relat program abovesourc william blair estimatesexhibit scienc inc fair valuesourc compani report william blair estimatesexhibit scienc inc hiv franchis revenu regimen regimenstaf regimensatriplatruvadacompleraodefseydescovystribildgenvoyab/f/tafu patent expir date william blair
sourc compani report william blair estimatesexhibit scienc inc hcv global market import disclosur
